Hello !
Interesting charts !
http://stockcharts.com/def/servlet/SC.web?c=DNAG
Regards.
Evgeny.
Yes, looks like it wants to start its way back up again...good volume.
Are u in? i'm considering...price is still on the low side.
thanks,
julia
Hello !
DNAPrint genomics' Business Partner Biofrontera AG Completes 20 Million Euro Bond Placement
Tuesday September 6, 7:00 am ET
SARASOTA, Fla., Sept. 6, 2005 (PRIMEZONE) -- DNAPrint(tm) genomics, Inc. (OTC BB:DNAG.OB - News), which holds an 18% stake in German pharmaceutical company Biofrontera AG, today announced that Biofrontera has completed a 20 million euro bond placement.
ADVERTISEMENT
The bonds began trading on the Frankfurt exchange on Wednesday, August 31, under the symbol (ISIN DE 000 A0E 964 9). If Biofrontera completes a public offering in the future, each purchaser in the offering at 100 euros can convert to 6.2 shares of Biofrontera stock. This conversion rate attributes a price of 16.13 euros per share to the Biofrontera common shares. If this accurately represents the fair market value of the Biofrontera common stock, then DNAPrint's 455,179 shares of Biofrontera stock, which it acquired for 1.5 million euros in July 2005, would now be valued at approximately 7.3 million euros.
``We believe our investment in Biofrontera will prove to be beneficial to DNAPrint genomics and to our shareholders,'' said DNAPrint genomics President and Chief Executive Officer Richard Gabriel. ``It validates our decision to build a collaborative relationship with Biofrontera in advance of its anticipated initial public offering.''
``Biofrontera is an excellent business partner for us because of its drug-product pipeline,'' said Hector J. Gomez, Ph.D., Chairman and Chief Medical Officer at DNAPrint genomics. ``We are pleased with our relationship with Biofrontera, and we have the highest confidence in its management team. We are confident the new funding will assist Biofrontera in advancing its drugs into the market.''
Mr. Gabriel and Dr. Gomez both are members of Biofrontera's Board of Directors.
``DNAPrint genomics, Inc. and its support were crucial to our securing this new financing,'' said Prof. Hermann Lubbert, Chief Executive Officer of Biofrontera AG. ``We look forward to building our relationship with DNAPrint and believe that the synergy of the two companies and their technologies may offer a faster, cheaper and more effective way to develop drugs,'' he concluded.
Biofrontera already is in Phase II clinical trials for its lead product, an anti-itch compound for chronic Urticaria, or chronic itching. It also has a Phase II clinical trial compound for pre-cancerous skin lesions. In addition, Biofrontera has advanced several compounds to pre-clinical development, including a novel prophylactic migraine treatment.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a ``Super EPO'' (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(tm) RETINOME(tm) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(tm), and EURO-DNA(tm). Recently announced and as a part of the Company's Trace Genetics acquisition, DNAWitness-Y and DNAWitness-Mito are two new tests that can be used as identification tools when other DNA testing either fails to yield results or the sample might be too deteriorated.
About Biofrontera AG
Biofrontera is aiming to become a specialty pharma business in dermatology and inflammatory diseases. The company is located in Leverkusen, Germany. Biofrontera's existing investor group includes Heidelberg Innovation, TechnoMedia Kapitalbeteiligungsgesellschaft Koln mbH, and Prof. Dr. Riesner, founder of Quiagen AG. The financial resources provided by the bond will be applied to the further development of Biofrontera's clinical products. The bond will be placed on the Frankfurt Exchange under the symbol (ISIN DE 000 A0E 964 9).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact:
DNAPrint genomics, Inc.
Richard Gabriel, CEO and President
941-366-3400
The Wall Street Group, Inc.
Ron Stabiner
212-888-4848
(//)
In my only post on here this is one of my big picks for future. Hold it for several years. This and BLYC.ob
Though the DNAG might have more potential once they get the drugs on market. Look at what
Genentech Inc. (DNA)
did.
$41-$94 in less then 1 year. Once DNAG gets the ball rolling. It will skyrocket up so fast you won't be able to get in anymore.
Buy it when people bash the stock. That is only chance to get it for pennies.
Hey Iamtheman, Looks oversold. What do you know about the company? Looks interesting to me. Any info would be appreciated.
Thx
This page here shows you the product pipeline and how far they are into them.
http://www.dnaprint.com/welcome/pipeline/
This is the grandaddy page.
http://www.dnaprint.com/welcome/investorrelations/
Check them out guy. Worth the investment.
Hi !
http://www.market-pulse.com/eyiiprofile.htm
DNAG - UP 15%
VOL - 1.409.032
(//)
Good luck.
Evgeny.
Anyone catch them on COURT TV last night at 9pm? Cool stuff. I would back the truck up and load up. Better yet, back 3 trucks up!
This is better then 1 share of Google any day this stock.
Opened a position at $.0257. ;) I agree that the stock is oversold. The company is loosing money, but something big must be brewing.
A 20 Million Euro Bond Placement for Biofrontera is significant and DNA Print has an 18% stake in Biofrontera, which may have a public offering.
"If Biofrontera completes a public offering in the future, each purchaser in the offering at 100 euros can convert to 6.2 shares of Biofrontera stock".
This is a lot of seed money. They must have a high expectation of Biofrontera having a public offering.
IMO This would cause DNAG stock to greatly appreciate from it's puny $1.8MM market cap.
poorman1
Looking at the RSI this should bounce any day now, why oversold so I am in tommorrow morning. >:D Going to play the bounce. My predition on this will be .10-.12 cents bouncing through through.
Quote from: higherstocks on September 16, 2005, 01:05:00 AM
Looking at the RSI this should bounce any day now, why oversold so I am in tommorrow morning. >:D Going to play the bounce. My predition on this will be .10-.12 cents bouncing through through.
I bought this stock at an average of 0.22 before DNAG split 20-1. Then the price slipped down to as low as 0.065. Now it is climbing up. Do you think that this stock will go as high as 0.12 or would it at least go back to its original 0.22.
TIA
This thing is so oversold I think this is skyrocketing to .18 next week.
Quote from: higherstocks on September 17, 2005, 12:29:56 AM
This thing is so oversold I think this is skyrocketing to .18 next week.
Higherstocks,
Do you think this will go higher than its initial 0.22 in the coming weeks? As I said I bought it before the split of 20 to 1 and that was low at that time. I just want to know if it will regain at least its original value.
Thanks for all your help.
-digitx
Im not sure but I do know that this is way oversold. If I were you I would buy more at this level and really bank. Nothing is 100% but when I see RSI so low it is almost a given that when it does rebound it will explode.
Thanks for the great advice. Monday morning I will get more at this low price then if and when it goes to say 0.18 it will balance out and make a profit.
Thank you again. I really appreciate your help and prompt response.
-digitx
Just bought the 2nd half of my intended position @ $.0163. Trying to remain cool, despite the stock continuing to drop. 8)
I am anticipating some buyer interest during and after tomorrow's presentation at the New York Society of Security Analysts Medical Services Industry Conference.
http://biz.yahoo.com/pz/050912/85748.html
DNAPrint genomics to Present at New York Society of Security Analysts Medical Services Industry Conference
Monday September 12, 10:44 am ET
SARASOTA, Fla., Sept. 12, 2005 (PRIMEZONE) -- DNAPrint(TM) genomics, Inc. (OTC BB:DNAG.OB - News) announced today that president and chief executive officer Richard Gabriel will be presenting at the Medical Services Industry Conference sponsored by The New York Society of Security Analysts (NYSSA) on Wednesday, September 21, at The Harvard Club, 27 W. 44th St., in New York City, at 3:10 p.m. Eastern time.
Mr. Gabriel will provide an overview of DNAPrint genomics and its recent activities in the area of pharmacogenomics. Specifically, Mr. Gabriel's presentation will focus on how the company utilizes recent genomics and chemistry advances to develop next-generation drugs (``theranostics'') maximizing efficacy and minimizing side effects by tailoring medications for specific individuals
This is like the best OTC stock you can buy along with BLYC.ob
I think someone is shorting this stock every day or a group of people are doing it. How do you stop it?
Ive seen stuff like this happen. No bad news on the stock is out. You just got people shorting it. I hate those people that do that. That's when you have no brains to pick a stock, you gotta make money the easy way.
Someone should email DNAG and let them know about it, and ask what they can do to investgate it.
This stock is on the Nasdaq short list every single day.
I've been holding on to this stock for the longest time. It cost me an average of 0.22 before the 20 to 1 split. since then its been going downhill. I am a believer in this product and also in the success of the company. But i also believe that there are some people who are shorting this stock on a daily basic. My investment is worth no more than a couple hundred dollars today. I would like to know if we can do something such as contacting the company or something to inform them of the situation and our dissatisfaction. :o :( >:(
Good luck to all.
-digitx
What has compounded the problem, is that the company continues to sell shares to raise capital.
However, the price to book value is now 1.2 to 1, since book value is $0.015, according to Yahoo!Finance.
I'm holding at least until the end of the week. You never know, $.0161 may end up being a 52-week low. :D
Anyone has any info about this monster. I really need to see if others aree suffering tha same thing as me. This stock is going down and down and down with no break insight. I appreciate any help or info.
TIA
Digi, Ive been accumalating shares the rsi stands at 15. Any kind of good PR or buying interest will get this stock going it is way oversold. The break will be coming soon! And when it does hold on to your hats. >:D
Quote from: higherstocks on September 27, 2005, 01:19:53 AM
Digi, Ive been accumalating shares the rsi stands at 15. Any kind of good PR or buying interest will get this stock going it is way oversold. The break will be coming soon! And when it does hold on to your hats. >:D
Thank you Higherstocks. You always make me feel at ease after a long stress with my little stocks. I hope this thing will fly soon. ;)
Thank you again.
DNAG begins a radio advertising campaign and looks to be increasing PR. I take it this is an AM news station. Maybe the 52-week low has already been reached at $.0125 the other day. Yesterday, it looks like it bounced a little.
DNAPrint genomics Launches Radio Advertising Campaign for ANCESTRYbyDNA on 1010 WINS, a Popular All-News Media Outlet in New York City
Thursday September 29, 7:00 am ET
SARASOTA, Fla., Sept. 29, 2005 (PRIMEZONE) -- DNAPrint(tm) genomics, Inc. (OTC BB:DNAG.OB - News) today announced that it has launched a radio advertising campaign for its ANCESTRYbyDNA(tm) consumer product with 60-second spots being broadcast by 1010 WINS, a popular all news station serving the New York City Metropolitan area.
``With the growing popularity for family ancestry research, DNAPrint genomics is taking its message to consumers through a well-known mass-market media outlet,'' stated President and Chief Executive Officer Richard Gabriel. ``Our ANCESTRYbyDNA genome-based test that determines genetic heritage is an excellent tool for individuals or groups interested in learning about their ancestry and lineage.''
The advertising spots are being aired by 1010 WINS at various times throughout the day
Starting to really move. >:D
I don't know what to make of this. Is this setting up for a nice upward move? I don't know, but I will continue to hold.
Any thoughts would be appreciated.
As I mentioned earlier, I have been holding this stock for months. Higherstocks and I believe that this is a gem. So hold on. That is the best advice i can give right now. 8)
Two up days an increasing RSI is a good sign. We need this to move across 30 and it will attract alot of buyers. If we do indeed have another up day tommorrow which moves through RSI 30 it should explode. What happens is when it crosses 30 it hits alot of scans and you get alot buying pressure. Lets see if this will happen with DNAG.
Quote from: higherstocks on September 29, 2005, 11:38:32 PM
Two up days an increasing RSI is a good sign. We need this to move across 30 and it will attract alot of buyers. If we do indeed have another up day tommorrow which moves through RSI 30 it should explode. What happens is when it crosses 30 it hits alot of scans and you get alot buying pressure. Lets see if this will happen with DNAG.
Hi Higherstocks,
Can you please post a chart here to see RSI 30. I am new to technical analysis and would like some explanation. Please post if you have the time.
TIA
Relative Strength Index (RSI) is an extremely useful and popular momentum oscillator. The RSI compares the magnitude of a stock's recent gains to the magnitude of its recent losses and turns that information into a number that ranges from 0 to 100. It takes a single parameter, the number of time periods to use in the calculation. In his book, Wilder recommends using 14 periods.
The RSI's full name is actually rather unfortunate as it is easily confused with other forms of Relative Strength analysis such as John Murphy's "Relative Strength" charts and IBD's "Relative Strength" rankings. Most other kinds of "Relative Strength" stuff involve using more than one stock in the calculation. Like most true indicators, the RSI only needs one stock to be computed. In order to avoid confusion, many people avoid using the RSI's full name and just call it "the RSI."
Calculation
(http://rsi-formula1.gif)
To simplify the formula, the RSI has been broken down into its basic components which are the Average Gain, the Average Loss, the First RS, and the subsequent Smoothed RS's.
For a 14-period RSI, the Average Gain equals the sum total all gains divided by 14. Even if there are only 5 gains (losses), the total of those 5 gains (losses) is divided by the total number of RSI periods in the calculation (14 in this case). The Average Loss is computed in a similar manner.
Calculation of the First RS value is straightforward: divide the Average Gain by the Average Loss. All subsequent RS calculations use the previous period's Average Gain and Average Loss for smoothing purposes. See the "Smoothed RS" formula above for details. The table below illustrates the formula in action.
(Click here for an Excel spreadsheet with this example in it.)
Here's how lines 14 and 15 were calculated:
Note: It is important to remember that the Average Gain and Average Loss are not true averages! Instead of dividing by the number of gaining (losing) periods, total gains (losses) are always divided by the specified number of time periods - 14 in this case.
When the Average Gain is greater than the Average Loss, the RSI rises because RS will be greater than 1. Conversely, when the average loss is greater than the average gain, the RSI declines because RS will be less than 1. The last part of the formula ensures that the indicator oscillates between 0 and 100. Note: If the Average Loss ever becomes zero, RSI becomes 100 by definition.
Important Note: The more data points that are used to calculate the RSI, the more accurate the results. The smoothing factor is a continuous calculation that - in theory - takes into account all of the closing values in the data set. If you start an RSI calculation in the middle of an existing data set, your values will only approximate the true RSI value. SharpCharts uses at least 250 data points prior to the starting date of any chart (assuming that much data exists) when calculating its RSI values. To duplicate its RSI number, you'll need to use at least that much data also.
Use
Overbought/Oversold
Wilder recommended using 70 and 30 and overbought and oversold levels respectively. Generally, if the RSI rises above 30 it is considered bullish for the underlying stock. Conversely, if the RSI falls below 70, it is a bearish signal. Some traders identify the long-term trend and then use extreme readings for entry points. If the long-term trend is bullish, then oversold readings could mark potential entry points.
Divergences
Buy and sell signals can also be generated by looking for positive and negative divergences between the RSI and the underlying stock. For example, consider a falling stock whose RSI rises from a low point of (for example) 15 back up to say, 55. Because of how the RSI is constructed, the underlying stock will often reverse its direction soon after such a divergence. As in that example, divergences that occur after an overbought or oversold reading usually provide more reliable signals.
Centerline Crossover
The centerline for RSI is 50. Readings above and below can give the indicator a bullish or bearish tilt. On the whole, a reading above 50 indicates that average gains are higher than average losses and a reading below 50 indicates that losses are winning the battle. Some traders look for a move above 50 to confirm bullish signals or a move below 50 to confirm bearish signals.
Example
The DELL example shows a number of extreme readings as well as a negative divergence. In Oct-99, RSI reached oversold for a brief moment to mark the low around 38. The next extreme reading (overbought) occurred after a large advance that peaked in Dec-99. RSI reached overbought levels in late Dec-99 and moved below 50 by the second week of Jan-00. The next oversold reading occurred in Feb. for another brief moment and marked the low around 35. By the end of Feb-00, RSI moved back above 50 and into overbought territory in March. A negative divergence formed in March and marked the high in the upper fifties.
Thank you Higherstocks. Very informative. However I can't see the charts or formulas if there are any. But overall i get the point.
Thank you again.
PS. Now I can see them at the bottm. Thank you.
I think we are setup for a big Monday and week. >:D
its been on the buyins list for 28 days...naked short selling...be careful.... :)
Forensics Technology Assists Police in Identifying Suspect in California Double Murder
Oct 3, 2005 7:00:00 AM
2005 PrimeZone Media Network
SARASOTA, Fla., Oct. 3, 2005 (PRIMEZONE) -- DNAPrint genomics, Inc. (OTCBB:DNAG) today confirmed that its DNAWITNESS forensics technology narrowed down a list of potential suspects during a police investigation that led to an arrest in the murder of two women in Napa, Calif.
The brutal stabbings of Leslie Ann Mazzara and Adriane Michelle Insogna, both 26, in a home they shared in the Northern California community, had stumped police for nearly 11 months because the women had no known enemies and there was no apparent motive. Police had speculated that the killer knew one or both of the victims.
Being held in custody was a man identified by authorities as Eric Matthew Copple, 26, of Napa. Police conducted more than 1,300 interviews during the investigation and collected DNA samples from 218 individuals, all men who had social or work contact with all three roommates who lived in the home. A third woman escaped unharmed during the Nov. 1, 2004, attack and called police.
The California Department of Justice Crime Lab and DNAPrint genomics previously determined that an analysis of blood samples collected at the crime scene indicated that the suspect was a male. Forensic evidence also pointed to a killer who smoked Camel Turkish Gold cigarettes, a hybrid of the popular cigarette brand. NapaPolice issued a statement to the media on Sept. 22, 2005, saying that DNAPrint genomics' forensics laboratory had further determined that the ancestry of the person of interest was white with 96% Northern European ancestry and 4% Southeastern European.
"We received a DNA sample from the Napa Police on Nov. 23, 2004 and returned the results of our DNAWITNESS analysis two days later," stated DNAPrint genomics President and Chief Executive Officer Richard Gabriel. "More recently, the case was revisited when DNAPrint was asked to analyze the sample with our EUROWitness technology to further refine the information. With information from DNAPrint, the Napa Police Department did a media release describing a white male adult who smokes or did smoke Camel Turkish Brand Cigarettes."
The San Francisco Chronicle newspaper reported that Napa Police Department Investigations Bureau Commander Jeff Troendy confirmed that DNA-related evidence and the media release led to the arrest of Copple. Troendy was quoted as saying, "The media release last week helped us get to this point, sometimes things happen very quickly."
About DNAPrint genomics, Inc.
Today's activity looks bullish, but then again, this stock has had many, many false rallies.
One thing which is promising is that the PR blitz is likely to continue.
Volume 8.5MM
Good luck,
poorman1
Here's the updated DNAG chart at the end of Monday, Oct. 3, 2005.
I'm not sure if this indicates a gap-down tomorrow or what tomorrow.
Good luck,
poorman1
Im liking the chart, I think we could see an explosion in the stock price. I like the improving RSI and the vokume today! This is an early indication of a big pps increase. Now I think this is a good indication that we will have a good PR coming also. Remember MM's control the price and I believe that they will be selling at a much higher pps.
DNAPrint genomics Receives Notice of Allowance for Patent for Processing Gene Sequence Data
10/27/2005 07:00
SARASOTA, Fla., Oct. 27, 2005 (PRIMEZONE) -- DNAPrint genomics, Inc. (OTCBB: DNAG), a developer of genomics-based products and services, today announced that it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its patent application for Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data.
"Though we are all 99.9% identical at the level of our DNA, it is the 0.1% difference called polymorphism that accounts for our individuality," stated Tony N. Frudakis, Ph.D., DNAPrint's founder and Chief Scientific Officer. "The technology our patent application covers relates to methods useful for measuring polymorphisms in and around genes that are part of large gene families, a task that traditionally has been problematic for the molecular genetics community."
Geneticists use "molecular addresses" to query and study specific genes much like a postman uses a street address to find the recipient of a letter. The methods covered in the patent are useful when there are several genes with the same or substantially similar "sequence" addresses. Many of the genes that are involved in drug metabolism and response are members of large gene families.
This is the first patent for which the Company applied. The methods covered in the application, first drafted in 2001, were originally developed to power DNAPrint's unique approach to pharmacogenomics research, which is aimed at understanding why people respond uniquely to drugs.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS, RETINOME, ANCESTRYbyDNA and EURO-DNA.
Forward Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
CONTACT: DNAPrint genomics, Inc.
Richard Gabriel, President and CEO
(941) 366-3400
The Wall Street Group, Inc.
Ron Stabiner
(212) 888-4848
This one is so hated by investors and so loved by shortsellers naked or not. So much that the stock looks like a steal at current PPS.
Market cap now is only 894.53K @.0141
Price/Sales (ttm): 1.00
Price/Book (mrq): 0.94
last PR about patent should increase book value some too.
What´s interesting is:
number of shares outstanding has stayed at 63.44M since July 12. This could be a sign that DNAGs burnrate is low now or even better they are cash flow positive? That would mean the dilution death spiral has stopped.
The reaction from the market to the news releases haven't been that strong. Anyway, the news has had more financial significance for every release.
Will be very interesting to see how market takes this latest piece of news.
Hello.....may be ready to make a run north.
Maybe it is about time. ;)
No news and up 10% on good volume. Momentum is definitely picking up.
poorman1
Hello.....on the move ! ;D
+17.83%......Volume @........2,686,571.......Let's rock ! 8)
The company DNAG is going to acquire appears to be legitamite. The executives seam to be well established in their fields. Here's the companies website:
http://www.kennatechnologies.com/about.html
Here's the 5-day chart on DNAG. The spike this morning did not result in a huge selloff. Looks as if it could go much higher as accumulation occurred in the afternoon.
poorman1
Stock of the day...
Buy DNAG without no doubt...Great news and great chart
News : cf. previous topics
Technicals :
Gap
High volume
Good support with volume accumulation
News this morning. I don't make much of this, but at least it leaves me to believe there is activity going on at DNAG.
http://biz.yahoo.com/iw/051104/0100172.html
DNAPrint Genomics Executives to Attend World Drug Discovery & Development Conference in Copenhagen
Friday November 4, 7:00 am ET
SARASOTA, FL--(MARKET WIRE)--Nov 4, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BB:DNAG.OB - News), a developer of genomics-based products and services, today announced that it will be participating in the World Drug Discovery & Development Summit on Tuesday and Wednesday, Nov. 29-30, 2005 in Copenhagen, Denmark.
"The Summit comes at a time when DNAPrint genomics is actively pursuing the development of pharmacogenomic products that include test/drug combinations based on inherited gene characteristics. These test/drug combinations are designed to optimize patient response and improve efficacy," stated Hector J. Gomez, M.D., Ph.D., the Company's Chairman and Chief Medical Officer. "The Summit is an excellent opportunity to participate in targeted meetings with pharmaceutical industry representatives and to discuss our Company's advances in the field of personalized medicine."
Other top DNAPrint executives attending the summit, which is sponsored by the London-based World Trade Group, are President and Chief Executive Office Richard Gabriel and Company Founder and Chief Scientific Officer Tony N. Frudakis.
"This conference presents us a forum to showcase not only our drug development, but also how our technologies, products and services can help the pharmaceutical companies accelerate their own research and development programs," Mr. Gabriel said.
"The development of pharmaceuticals that improve the quality of life for medical patients has been an over-riding goal of our Company from its beginning," Dr. Frudakis stated. "Our research in drug development is well under-way and our newly formed DNAPrint Pharmaceutical subsidiary emphasizes the importance we place on this objective."
Another huge volume day in the works, may be the biggest volume of the year. Up another 18%. May act like AMEP, wouldn't that be nice. :D
Great find guys. (Applauding all of you) Chart looks promising for a run monday!
>:D
calven
What do you think guys about DNAG in term of regaining its value? In June, I bought the share for 0.22 and then they split the shares 20 to 1. Since then it went down to almost nothing.
I know the rise in its value is good for the new buyers but does not give me back what I paid by a long shot. I am still down about 90%. Does anyone think it will be up to the 0.22 level gain?
TIA :-\
Hey digit,
I think it would have a tough time of ever reaching .22 in the near future. With a 20-1 split shares are seriously diluted. This makes it very hard for the stock to move higher. High supply of shares and low supply of buyers. Its definately possible but not very likely. Reverse splits are almost always a "death trap"
DNAG should see a nice pop but I think .22 is out of the question unless big news is released.
Happy trading,
calven
Quote from: calven on November 04, 2005, 11:00:14 PM
Hey digit,
I think it would have a tough time of ever reaching .22 in the near future. With a 20-1 split shares are seriously diluted. This makes it very hard for the stock to move higher. High supply of shares and low supply of buyers. Its definately possible but not very likely. Reverse splits are almost always a "death trap"
DNAG should see a nice pop but I think .22 is out of the question unless big news is released.
Happy trading,
calven
Thanks Calvin.
But is there something i should do now to regain my investment. maybe buy more at the current price and then the profit will make up for the original losses.
TIA
I don't think I have anything to say that will help you out. I don't really think I would add to a losing position. Probably better to leave what you have work being down 90%. I do think DNAG will continue its short term run on monday.... more of a swing/momentum trade -
DNAPrint(TM) genomics, Inc., a developer of genomics-based products and services, today announced that it will be participating in the World Drug Discovery & Development Summit on Tuesday and Wednesday, Nov. 29-30, 2005 in Copenhagen, Denmark.
"The Summit comes at a time when DNAPrint genomics is actively pursuing the development of pharmacogenomic products that include test/drug combinations based on inherited gene characteristics. These test/drug combinations are designed to optimize patient response and improve efficacy," stated Hector J. Gomez, M.D., Ph.D., the Company's Chairman and Chief Medical Officer. "The Summit is an excellent opportunity to participate in targeted meetings with pharmaceutical industry representatives and to discuss our Company's advances in the field of personalized medicine."
Other top DNAPrint executives attending the summit, which is sponsored by the London-based World Trade Group, are President and Chief Executive Office Richard Gabriel and Company Founder and Chief Scientific Officer Tony N. Frudakis.
"This conference presents us a forum to showcase not only our drug development, but also how our technologies, products and services can help the pharmaceutical companies accelerate their own research and development programs," Mr. Gabriel said.
"The development of pharmaceuticals that improve the quality of life for medical patients has been an over-riding goal of our Company from its beginning," Dr. Frudakis stated. "Our research in drug development is well under-way and our newly formed DNAPrint Pharmaceutical subsidiary emphasizes the importance we place on this objective."
DNAG showing bottoming action and 'cup and handle' forming - now with rising 20 dma as support. At current PPS the stock looks like a steal considering the market potential and how much money has been pumped into this company.
Dilution is of course an issue, anyhow IMHO this seems like good risk/reward play.
From the last 10-QSB: 'State the number of shares outstanding of each of the issuer's classes of common equity as of October 15, 2005 149,947,895 shares '.
This would make market cap 2.6 M$ @ 0.0174. Likely some more shares have been issued since. If someone would call the transfer agent and get current number and post it that would be useful.
Up 25% so far today.
+28% today - as I write
IMO The longer DNAG takes to break $.03 the better. I'm wanting a long-sustained rally, like AMEP. We shall see. Sitting on a 52% gain @ $.0255, but I am expecting much more from this bullish move.
poorman1
Quote from: setravis on November 02, 2005, 11:59:48 AM
Hello.....may be ready to make a run north.
Nice volume and price action today.
Such a cheap Stemcell related stock.
very strong close. this one looks ready to fly next week. kudos to all those who called it prior to today.
Quote from: Stocksquire on November 25, 2005, 01:06:27 PM
very strong close. this one looks ready to fly next week. kudos to all those who called it prior to today.
Anyone knows how high this could go? Would it regain its original price of 6 months ago 0.19 - 0.22?
TIA
Pre-market indicates $.0395 - $.041. I think I will profit take on this spike, looking for the low $.04's to sell 50% of my position.
Wow ! what a dump ! I took your advice poorman, took half off. Maybe should have taken all ? ???
elr :)
8)
DNAPrint genomics to Present at Investor Conference Sponsored by the Wall Street Analyst Forum
SARASOTA, FL -- (MARKET WIRE) -- 11/18/2005 -- DNAPrint™ genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that Dr. Barbara Handelin, the Company's General Manager of Computational Biology, will be presenting before The Wall Street Analyst Forum Institutional Investor Conference at The Roosevelt Hotel, Madison Avenue at 45th Street, in New York City at 11:00 a.m. Eastern time on Wednesday, November 30.
During the 40-minute presentation, which can also be heard via a live webcast on the Company's website at www.dnaprint.com or at http://www.investorcalendar.com/CEPage.asp?ID=97888, Dr. Handelin will provide an overview of the Company and discuss its goals and outlook for the future. The webcast will also be archived. To register for the conference, please visit www.analyst-conference.com or contact The Wall Street Group, Inc. at 212-888-4848.
The Wall Street Analyst Forum brings together financial analysts and portfolio managers who are interested in learning about the companies participating in the investor conference and provides them the opportunity to personally meet company personnel and learn more about the company.
if we hold 0.023 we are fine....trendline intact....so far...down on little volume is good i am not worried
Thanks for the chartwork. Based on your post, I got an order filled at $.0215 this morning.
Applaud
I'm looking for a hammer support today.
Good luck,
poorman1
we just broke the day high...wow...good re-entry poorman..i am glad for you :o
this stock seems to bounce back today
The chart is a thing of beauty. Holding :)
;D charts looks good up on the trendline with good volume; retracements with low volume..good!
Here we have a 2 year chart on a weekly basis. I see big resistence around 0.032 (2. green line) if we break this line we would be back in the downchannel...could then hit the 1. green line at around 0.2.
1. volume is huge
2. rsi is rising
3. macd is getting positve
4. last run in april/may dnag was up 600% but on very little volume !!!
5. we need patience here..reward is coming big volume never lies.
Any comments ? 8)
Is it possible for it to go up 600% as it did before? Can we see a price range in the 0.2 - 0.25?
TIA
I dont make predictions...as long we trade up on the trendline i am in.....i trade based on charts...so far it looks good...volume is high 8)
Quote from: ket1390 on December 03, 2005, 05:46:27 PM
I dont make predictions...as long we trade up on the trendline i am in.....i trade based on charts...so far it looks good...volume is high 8)
Thank you.
7.7M traded and up 18%... rock on :)
Adding a bit to my position on our way up here... but will wait to see if we can break 0.044 (big res. point).
Yessssuh... Stack it.
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=11233;image)
thoughts about this chart anybody...
thanks. :)
News and volume...
http://biz.yahoo.com/iw/060126/0107479.html
http://biz.yahoo.com/prnews/060126/phth013.html?.v=44
News out:
http://biz.yahoo.com/iw/060203/0108560.html
Newsweek.
Been holding, still holding :) Looks pretty on the charts right now, so I'm all warm inside.
A few notes:
We've seen volume days in the past week and a half that have been double in size for positive days (versus negative days). This may signal some accumulation is occuring. Pullbacks on weaker volume, and last two days have seen higher and high volume and higher and higher price.
Also, the 0.023 mark has been broken. This is one of the three key res. points on upward. Obviously we'll have to wait and see if she can make it past the last .028 and then finally .03 - at which point I'll probably add a few shares and then more only if we can break 0.044.
Anyway - I've no stops since I've so little capital invested.
Tech looks good, could be ready to go.
News:
http://biz.yahoo.com/e/060207/dnag.ob8-k.html
I like the volume :)
Watching the res. points for addition, nearing :)
I like to watch if I get a chance to (that is... I'm not sitting in class).
Lots of nice large uptick purchases here at the end of the day. Volume closing in on 25mil. I think we'll get to perhaps 26m.
@10.52AM: vol @ ~17mil
up 10%
small gap up
broke .03 res.
I would not give up on this one, with only 149,948,000 shares and oversold and support at .023. They are coming out with lots of news: http://finance.yahoo.com/q?s=DNAG.OB
Check what happened last April and now it is oversold. I like that little cup and handle.
Holding. This looks like it could be a great 1-2 month setup, I'm not looking to drop any of my shares anytime soon. I like the steady climb. Great pattern.
http://tinyurl.com/cvber
Slowly, steadily nearing some very key res. points. The chart is pretty.
Chart continues to look pretty. Still holding on, looking for strong breakout.
Today's range, it is trying to breakout. Lots of news lately:
http://finance.yahoo.com/q?s=DNAG.OB
Looking good.
http://biz.yahoo.com/iw/060314/0112989.html
Crossed it's .03 resistance,next res is at .04.
big big news....it is going to move big...compound more potent than epo
erythropoeitin sales are big money maker
amgen profits based on epo sales
Quote from: kidneydr on December 08, 2006, 10:30:54 AM
amgen profits based on epo sales
DNAPrint Announces Discovery of Genetic Marker for Statin-Induced Myalgia
Tuesday December 19, 7:00 am ET
Findings From Company's Statnome Project Successfully Validated; Article on Study to Be Published in Noted Academic Journal
SARASOTA, FL--(MARKET WIRE)--Dec 19, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News), today announced that the Company's research staff has discovered a genetic marker for statin-induced myalgia (chronic muscle pain), that a patent has been filed to protect the discovery and that the research on which the discovery is based will be published in an upcoming issue of The Journal of Pharmacogenetics and Genomics (JPG).
The marker was the primary discovery from the Company's Statnome project initiated in 2000 and the manuscript to be published in JPG describes the validation of this finding in different patient samples.
"Myalgia or chronic muscle pain is a common side effect reported by patients who take statins for cholesterol control, and it is likely to be part of a disease continuum that includes myositis and rhabdomyolysis, which is a breakdown of muscle fibers that frequently results in kidney damage and is a potentially fatal side-effect," according to DNAPrint Chief Science Officer Tony Frudakis, Ph.D. "Deaths associated with statin-induced rhabdoymyolysis lead Bayer to withdraw Cerivistatin in 2001. We are satisfied to have brought one of our first pharmacogenetics programs full circle from discovery through validation and we consider the R&D phase for this project complete. With the filing of a patent to protect this discovery, the Company will be able to develop a proprietary test for this gene variant and thereby reduce the likelihood of illness or death in those patients who are taking statins. This study also criticizes the original clinical trials for statins, which did not fully or adequately explore the relationship between statins and myalgia or even rhabdomyolysis."
"This is the culmination of a project that was begun when the company was founded," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "It has taken until now to validate the original findings, but validated they are. The Company has filed a patent to protect this process. We plan to bring to market a definitive test product to identify this genetic variant and to potentially prevent painful -- and in some cases, fatal -- side effects in thousands of patients who are taking a very common prescription drug."
DNAPrint's study of 750 patients who had taken either atorvastatin (Lipitor®) or simvastatin (Zocor®) showed that patients carrying one specific genetic marker were approximately 2.5 times more likely to experience mild to severe muscle pain (myalgia). The effect was most pronounced for atorvastatin and the study showed that approximately one half of the patients who were removed from atorvastatin therapy due to muscle symptoms possess this genetic marker, whereas in the general population (with and without cardiovascular disease) only approximately 15%-25% of people carry the marker. DNAPrint applied its technology for measuring population structure (e.g., ancestry) in order to prove that the finding in both the discovery and validation samples was genuine, and in so doing received praise from JPG reviewers. This observation indicates that the genetic marker may be related not only to response to statins but also to a possible relationship with higher cholesterol levels, according to the study.
"DNA Print Genomics was founded on the underlying genomic screening methods developed to more efficiently scan the genome for medically important genetic markers of drug responses," stated Dr. Frudakis. "The current findings are another example of the efficiency of the Company's methods."
We've got to get by this .0175 level and then we could be off to the races. Volume needs to pick up though.
Partnering with the fine people at Code Amber (Amber Alerts). Wonder if this will get this thing past the .0175 level. That's been some stiff resistence for this thing.
Finally got past resistence although I wish volume was a bit higher. Could get interesting from here.
Filed this 8k. They sold much of their stake in Biofrontera. Could get a pop depending on how they choose to spend the money.
http://biz.yahoo.com/e/070305/dnag.ob8-k.html
http://www.bradenton.com/mld/bradenton/business/16502822.htm (http://www.bradenton.com/mld/bradenton/business/16502822.htm)
Both Gomez and DNAPrint Genomics will also be part of a massive research initiative announced last month by the H. Lee Moffitt Cancer Center & Research Institute of Tampa. The center said it would partner with an affiliate of Merck & Co., Inc. pharmaceutical company to expand biotechnology research with the goal of developing personalized medicine.
Merck and Moffitt will form a for-profit company, called M2GEN, that will develop personalized cancer treatments using a patient's genetic profile.
City Vote for M2GEN founding is on the 15th,State and county are approved. ;)
Looks good....
Next week could get interesting...
I like the chart. It's set up for a nice run, especially since the city council votes this week on the M2GEN funding. DNAG is said to be involved with Merck. I emailed the company and they basically told me more info would be made available after the vote. Good luck.